Medtronic touts atrial fibrillation treatment at Heart Rhythm Society conference

May 14, 2010 by MedCity News

Minnesota medical device giant says patients suffering from atrial fibrillation (AF), or irregular heart quivering, reported significantly less symptoms after using its cryoablation technology.

MedCity News logo

By Thomas Lee

Medtronic Inc. (NYSE: MDT) said patients suffering from atrial fibrillation (AF), or irregular heart quivering, reported significantly less symptoms after using its cryoablation technology.

At the Heart Rhythm Society's annual scientific conference, the Fridley, Minnesota -based company continued its systematic campaign to scientifically validate its Artic Front Cardiac Cryoablation Catheter system by releasing the latest results from its pivotal STOP AF clinical trial of 275 patients.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp